• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

    11/27/24 8:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care
    Get the next $APYX alert in real time by email

    CLEARWATER, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, in New York, NY.

    Charlie Goodwin, the Company's President and Chief Executive Officer, and Matt Hill, the Company's Chief Financial Officer, will participate in a fireside chat on Wednesday, December 4, 2024, at 4:00pm ET and will hold one-on-one meetings with investors throughout the day. The fireside chat will be accessible via live webcast here, and a replay will be available on the Events section of Apyx Medical's Investor Relations website at https://apyxmedical.com/investor_relations/.

    About Apyx Medical Corporation:

    Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people's lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

    Investor Relations Contact:

    Jeremy Feffer, Managing Director LifeSci Advisors

    212-915-2568

    [email protected]  



    Primary Logo

    Get the next $APYX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APYX

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    7/14/2023$8.00Overweight
    Stephens
    5/20/2022$12.00Buy
    Lake Street
    8/13/2021$12.00 → $14.00Market Outperform
    JMP Securities
    More analyst ratings

    $APYX
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Announces Board Leadership Transition

      Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

      5/9/24 7:00:00 AM ET
      $APYX
      $BVS
      $XTNT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

      Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

      11/28/23 8:30:00 AM ET
      $APYX
      $PDSB
      $SSKN
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

      NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

      3/1/22 4:05:00 PM ET
      $APYX
      $LNTH
      $PRTK
      $SCPH
      Medical/Dental Instruments
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Pharmaceutical Preparations

    $APYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

      4/A - Apyx Medical Corp (0000719135) (Issuer)

      3/3/25 4:05:12 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Roman Shawn David

      4 - Apyx Medical Corp (0000719135) (Issuer)

      1/17/25 4:07:08 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Baylor-Henry Minnie

      4 - Apyx Medical Corp (0000719135) (Issuer)

      1/17/25 4:07:05 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Apyx Medical Corporation

      10-Q - Apyx Medical Corp (0000719135) (Filer)

      5/8/25 12:27:23 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Apyx Medical Corp (0000719135) (Filer)

      5/8/25 6:58:22 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Apyx Medical Corp (0000719135) (Filer)

      4/29/25 8:12:02 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Apyx Medical

      BTIG Research initiated coverage of Apyx Medical with a rating of Neutral

      10/17/24 7:28:31 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Stephens initiated coverage on Apyx Medical with a new price target

      Stephens initiated coverage of Apyx Medical with a rating of Overweight and set a new price target of $8.00

      7/14/23 7:29:43 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Apyx Medical with a new price target

      Lake Street initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $12.00

      5/20/22 8:54:50 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Hill Matthew C bought $6,780 worth of shares (6,000 units at $1.13), increasing direct ownership by 240% to 8,500 units (SEC Form 4)

      4/A - Apyx Medical Corp (0000719135) (Issuer)

      3/3/25 4:05:12 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Hill Matthew C bought $6,030 worth of shares (5,336 units at $1.13), increasing direct ownership by 213% to 7,836 units (SEC Form 4)

      4 - Apyx Medical Corp (0000719135) (Issuer)

      8/13/24 6:56:00 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Hill Matthew C bought $5,475 worth of shares (2,500 units at $2.19) (SEC Form 4)

      4 - Apyx Medical Corp (0000719135) (Issuer)

      12/14/23 9:00:19 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Financials

    Live finance-specific insights

    See more
    • Apyx Medical Corporation Reports First Quarter 2025 Financial Results

      Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March

      5/8/25 7:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

      CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Partic

      4/24/25 8:45:51 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

      CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of the fourth quarter and fiscal year 2024, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international call

      2/27/25 8:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Apyx Medical Corporation

      SC 13G - Apyx Medical Corp (0000719135) (Subject)

      10/31/24 5:44:01 PM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Apyx Medical Corporation

      SC 13G/A - Apyx Medical Corp (0000719135) (Subject)

      10/15/24 9:18:53 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Apyx Medical Corporation (Amendment)

      SC 13D/A - Apyx Medical Corp (0000719135) (Subject)

      5/9/24 7:45:22 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care

    $APYX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apyx Medical Corporation Reports First Quarter 2025 Financial Results

      Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last yearU.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last yearPreparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA clearanceManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its first quarter ended March

      5/8/25 7:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures

      Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin CLEARWATER, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform marketed and sold as Renuvion®, today announced the publication of two peer-reviewed clinical studies evaluating the use of Renuvion during body contouring procedures that also included lipoabdominopla

      4/29/25 8:00:00 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care
    • Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

      CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Partic

      4/24/25 8:45:51 AM ET
      $APYX
      Medical/Dental Instruments
      Health Care